Skip to main
VKTX

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics is positioned to be a top competitor in the biopharmaceutical development industry, with a strong pipeline including VK2809 and VK5211, as well as their recently completed IND filing for VK3019. With a favorable mix of potency and safety, VK2809 has the potential to be a best-in-class TRβ. The company has a strong cash runway that should support key value-driving milestones, and their ongoing flexibility to pursue strategic opportunities through partnerships or acquisitions adds to their overall value proposition.

Bears say

Viking Therapeutics is focused on developing therapies for metabolic and endocrine disorders, with a lead drug candidate, VK2735, in both oral and subcutaneous formulations. While the company has promising pipeline assets, there is a risk of commercial failure if Viking is unable to secure sufficient manufacturing agreements and if their oral program for VK2735 is not viable. The company's current financials in terms of revenue and partnerships may not be enough to support the commercialization and development of their drugs.

Viking Therapeutics (VKTX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Buy based on their latest research and market trends.

According to 9 analysts, Viking Therapeutics (VKTX) has a Buy consensus rating as of Jun 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $95.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $95.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.